Singapore markets closed

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.4600+0.0700 (+2.06%)
At close: 04:00PM EST
3.3500 -0.11 (-3.18%)
After hours: 08:00PM EST

Organogenesis Holdings Inc.

85 Dan Road
Canton, MA 02021
United States
781 575 0775
https://organogenesis.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees1,030

Key executives

NameTitlePayExercisedYear born
Mr. Gary S. Gillheeney Sr.President, CEO, Chair of the Board1.06M7.94M1955
Mr. David C. FranciscoChief Financial Officer473.14kN/A1966
Mr. Patrick BilboChief Operating Officer537.07kN/A1962
Ms. Lori H. Freedman B.A., Esq., J.D.Chief Administrative & Legal Officer489.41kN/A1967
Mr. Brian GrowChief Commercial Officer513.06k2.23k1976
Mr. Thomas L. PearlVice President of Human ResourcesN/AN/AN/A
Mr. William R. Kolb CPASecretaryN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary wound covering; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly AM, PuraPly XT, and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Corporate governance

Organogenesis Holdings Inc.’s ISS governance QualityScore as of 1 February 2024 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.